Carisma Therapeutics Announces FDA Clearance Of IND For CT-0525 - Quick Facts

(RTTNews) - Carisma Therapeutics Inc. (CARM) announced the clearance of Investigational New Drug application by the FDA for CT-0525 in treatment of solid tumors that overexpress human epidermal growth factor receptor 2. Carisma expects to initiate a Phase 1 study in the coming months and to treat the first patient in the first half of 2024.

The Phase 1 study for CT-0525 is designed to assess the safety, tolerability, and the manufacturing feasibility of CT-0525. The study will enroll participants with locally advanced or metastatic solid tumors overexpressing HER2 whose disease has progressed on standard approved therapies. The study will consist of two cohorts.

For More Such Health News, visit rttnews.com.